Guy Meyer

Tinzaparin Pharmacokinetics in Patients with Cancer: A Comparative Modeling Study

Xavier Delavenne, Jean Escal, Dominique Helley, Laurent Bertoletti et autres

Abstract Cancer-associated thrombosis (CAT) is common and a leading cause of mortality in patients with cancer. In specific CAT scenarios, low-molecular-weight heparins (LMWHs), including tinzaparin, are preferred over direct oral anticoagulants. Despite the importance of understanding LMWH pharmacokinetics (PK) in cancer for …

fr, ca (code pays fourni par la source)

Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism

Isabelle Mahé, Marc Carrier, D. Mayeur, Jean Chidiac et autres

BACKGROUND: In patients with active cancer and venous thromboembolism, whether extended treatment with a reduced dose of an oral anticoagulant is effective in preventing recurrent thromboembolic events and decreasing bleeding is unclear. METHODS: We conducted a randomized, double-blind, noninferiority trial with blinded …

fr, ca, es, us, nl, it, gr, pl, be, gb, at (code pays fourni par la source)

Extended treatment of venous thromboembolism with reduced-dose versus full-dose direct oral anticoagulants in patients at high risk of recurrence: a non-inferiority, multicentre, randomised, open-label, blinded endpoint trial

Françis Couturaud, Jeannot Schmidt, Olivier Sanchez, Alice Ballerie et autres

BACKGROUND: In patients with venous thromboembolism at high risk of recurrence for whom extended treatment with direct oral anticoagulants has been indicated, the optimal dose is unknown. We aimed to assess efficacy and safety of reduced-dose versus full-dose direct oral anticoagulants in …

fr (code pays fourni par la source)

Plasma tissue factor activity in lung cancer patients predicts venous thromboembolism and poor overall survival

H. Doubre, I. Monnet, R. Azarian, Philippe Girard et autres

Background Biomarkers to identify lung cancer (LC) patients with high risk of venous thromboembolism (VTE) are needed. Objectives To evaluate the usefulness of plasma tissue factor activity (TFA) and D-dimer levels for the prediction of VTE and overall survival in patients with …

fr (code pays fourni par la source)

Efficacy and Safety Outcomes in Patients with Cancer-Associated Thromboembolism Treated with Tinzaparin According to the Tumor Site: Meta-Analysis of Prospective Studies Involving 1413 Individual Patients' Data

Isabelle Mahé, Céline Chapelle, Luis Jara‐Palomares, Olivier Sanchez et autres

Introduction DOAC (direct oral anticoagulant) and LMWH (Low Molecular Weight Heparin) are recommended by international guidelines as first line therapy in patients with CAT (Cancer Associated Thrombosis), but the risk of venous thromboembolic recurrence (rVTE) and the risk of major bleeding (MB) …

fr, es, be (code pays fourni par la source)

French guidelines for the treatment of cancer-associated venous thromboembolism - 2023 update

Isabelle Mahé, Guy Meyer, Philippe Girard, Laurent Bertoletti et autres

BACKGROUND: In recent years, knowledge about cancer associated thrombosis has evolved considerably. METHODS: Practical guidelines were drafted on the initiative of the INNOVTE FCRIN Network, led by the French Speaking Society of Respiratory Diseases (SPLF), by a coordinating group, a writing group, …

fr (code pays fourni par la source)

Traitement de la maladie veineuse thromboembolique au cours du cancer Mise à jour Avril 2023

Isabelle Mahé, Guy Meyer, P. Girard, Laurent Bertoletti et autres

fr (code pays fourni par la source)

OC 11.2 Pulmonary Embolism Diagnostic Strategies in Patients with COPD Exacerbation: Post-Hoc Analysis of the Pep Trial

Vicky Mai, G Rambaud, Camille Motreff, O. Sanchez et autres

model, as determined by SHAP analysis.

ca, nl, jp, fr (code pays fourni par la source)

Pulmonary embolism diagnostic strategies in patients with COPD exacerbation: Post-hoc analysis of the PEP trial

G Rambaud, Vicky Mai, Camille Motreff, Olivier Sanchez et autres

fr, ca (code pays fourni par la source)

Pulmonary embolism diagnostic strategies in patients with COPD exacerbation: post-hoc analysis of the PEP trial

Vicky Mai, G Rambaud, Camille Motreff, Olivier Sanchez et autres

Background: The prevalence of pulmonary embolism (PE) is approximately 11-17% in patients with an acute exacerbation of chronic obstructive pulmonary disease (AE-COPD). The optimal diagnostic strategy for PE in these patients remains undetermined. Aims: To evaluate the safety and efficacy of standard …

ca, fr (code pays fourni par la source)

Cancer-Associated Thrombosis on Bevacizumab: Risk of Recurrence and Bleeding When Bevacizumab Is Stopped or Continued

M. Mayenga, Nicolas Falvo, Isabelle Mahé, Anne‐Sophie Jannot et autres

Cancer-associated thrombosis (CAT) is a common complication during cancer, with complex management due to an increased risk of both recurrence and bleeding. Bevacizumab is an effective anti-angiogenic treatment but increases the risk of bleeding and potentially the risk of venous thromboembolism (VTE). …

fr (code pays fourni par la source)

Enoxaparin versus Placebo to Prevent Symptomatic Venous Thromboembolism in Hospitalized Older Adult Medical Patients

Dominique Mottier, Philippe Girard, Françis Couturaud, Karine Lacut et autres

BACKGROUND: Admission to the hospital is a major risk factor for the development of venous thromboembolism (VTE). Whether thromboprophylaxis with low-molecular-weight heparin prevents symptomatic VTE in medically ill, hospitalized older adults remains debated. METHODS: In a prospective, randomized, placebo-controlled, double-blind, multicenter trial, …

fr, us, ch, ca (code pays fourni par la source)